rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    SF
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Tandem upgraded, Insulet downgraded at Stifel on market for tubeless insulin pumps

      Tandem Diabetes Care (TNDM) stock gains and Insulet (PODD) slips as Stifel changes their ratings, citing the market trends for tubeless insulin pumps. Read more here.

      8h agoSeeking AlphaPODDTNDMSF
      Lowe’s (LOW) Is Up Since October 7. Here’s Why Stifel Downgraded
      11h agoYahoo FinanceSF
      Tandem Diabetes shares climb 5% after Stifel upgrades stock to Buy
      12h agoInvesting.comTNDMSF
      Bridger Aerospace downgraded at Stifel, warning about restructuring (BAER:NASDAQ)
      13h agoSeeking AlphaBAERSF
      Stifel holds Nike stock rating at Hold with $36 target on delays
      16h agoInvesting.comSF
      Experian rises 4% as Panmure Liberum and Stifel back shares

      Experian PLC (LSE:EXPN) shares rose 4% to 2,936.29p in early trading after the data and technology company announced a $500 million buyback and raised its margin outlook despite narrowing revenue growth guidance. Panmure Liberum rated the shares ‘buy’ with a 4,200p target, while Stifel backed...

      16h agoYahoo FinanceSF
      Abeona Therapeutics Inc. (ABEO) Presents at Stifel 2026 Healthcare Conference 2026 - Slideshow
      Nov 17Seeking AlphaABEOSF
      Stifel expects Walmart to rally to new highs

      Analyst rates Walmart a Buy with a $145 target at 44x 2027 EPS, as its omnichannel platform should drive higher returns and valuation.

      Nov 17Seeking AlphaSFWMT
      Smart Eye data supports seasonal explanation for Seeing Machines royalty slowdown, Stifel says

      Seeing Machines Ltd (AIM:SEE, OTC:SEEMF) shares could benefit from evidence that its recent royalty slowdown reflects seasonal weakness in European vehicle production, rather than deteriorating underlying demand. Stifel analyst Peter McNally highlighted Smart Eye's third-quarter results as...

      Nov 17Yahoo FinanceSF
      Rightmove sale push meets Stifel scepticism over potential buyers

      Rightmove PLC (LSE:RMV) faces activist pressure to explore a sale, but Stifel remains sceptical about a near-term takeover, citing a shortage of obvious buyers. Stifel rates the shares ‘sell’ with a price target of 392p, implying a 32.7% downside to the 13 November closing price. Behind the...

      Nov 16Yahoo FinanceSF
      Lexeo Therapeutics stock gets Stifel buy rating on PKP2 data
      Nov 16Investing.comLXEOSF
      Victorian Plumbing tipped for growth as Stifel highlights Trade opportunity

      Stifel has initiated coverage on Victorian Plumbing Group PLC (AIM:VIC), the UK online bathroom retailer, with a 'buy' rating and 110p price target, implying 22% upside. Analyst Charlie Williams said the retailer offered attractive medium-term growth potential despite subdued consumer demand...

      Nov 16Yahoo FinanceSF
      What's Going On With Lowe's Companies Stock Friday?
      Nov 13BenzingaSF
      Lowe’s Stock Cut to Sell as It Struggles to Catch Up to Home Depot

      Stifel warns of margin pressure and costly investments as Lowe’s tries to catch up to Home Depot’s contractor business.

      Nov 13Barron'sHDSF
      Lowe's downgraded to sell as Stifel raises questions over homeowner's health

      Stifel analyst rates Lowe's a Sell, expecting shares to stay under pressure; FY27-FY28 margins could compress 20 bps versus consensus expansion of 34 bps.

      Nov 13Seeking AlphaSF
      Candel Therapeutics stock price target cut to $19 by Stifel on BLA delay
      Nov 13Investing.comCADLSF
      Here’s Why Stifel’s Jonathan Siegmann Still Backs SpaceX (SPCX) After Democratic Midterm Wins
      Nov 12Yahoo FinanceSPCXSF
      BioAge Labs at Stifel 2026 Healthcare Conference 2026: pivot to eye disease
      Nov 12Investing.comSF
      Stifel reiterates Buy on MaxCyte stock, cites Q3 growth momentum
      Nov 12Investing.comMXCTSF
      Stifel reiterates Buy on EPR Properties stock after debt offering
      Nov 12Investing.comEPRSF
      Pulse Biosciences at stifel 2026 healthcare conference: afib push builds
      Nov 12Investing.comPLSESF
      EVgo downgraded by Stifel as growth outlook weakens

      Stifel rates EVgo a Hold and cuts its target to $2.50 from $6 as slower EV adoption and fewer new stalls cloud its profitability timeline.

      Nov 12Seeking AlphaEVGOSF
      Maravai LifeSciences at Stifel 2026 Healthcare Conference: growth broadens
      Nov 12Investing.comMRVISF
      Ocugen at stifel 2026 healthcare conference: late-stage gene therapy push
      Nov 12Investing.comOCGNSF
      Mentari Therapeutics at Stifel 2026 Healthcare Conference 2026: migraine bid
      Nov 12Investing.comSF
      Could Rivian Actually Get Back to $22? Stifel Thinks So, Even as 2027 Loss Estimates Widen
      Nov 12Yahoo FinanceSF
      Syndax at Stifel 2026 Healthcare Conference: growth and pipeline push
      Nov 12Investing.comSNDXSF
      X4 Pharmaceuticals at Stifel 2026 Healthcare Conference: leaner path forward
      Nov 12Investing.comXFORSF
      SpyGlass at Stifel 2026 Healthcare Conference: data, scale and reach
      Nov 12Investing.comSF
      Mineralys at Stifel 2026 Healthcare Conference: launch focus builds
      Nov 12Investing.comMLYSSF
      Profound Medical at Stifel 2026 Healthcare Conference 2026: scaling TULSA-PRO
      Nov 12Investing.comSF
      Stifel reiterates Buy on Palo Alto Networks stock ahead of results
      Nov 12Investing.comPANWSF
      Compass Therapeutics at Stifel 2026 Healthcare Conference 2026: FDA path in focus
      Nov 11Investing.comCMPXSF
      Xenon at Stifel 2026 healthcare conference: epilepsy launch in focus
      Nov 11Investing.comSF
      Zymeworks at stifel 2026 healthcare conference: royalties, deals and growth
      Nov 11Investing.comZYMESF
      Tectonic Therapeutics at Stifel 2026 Healthcare Conference: 2027 catalyst push
      Nov 11Investing.comSF
      Zentalis at Stifel 2026 Healthcare Conference: dual path for azenosertib
      Nov 11Investing.comSF
      Rapport Therapeutics at stifel 2026 healthcare conference: cash-rich push
      Nov 11Investing.comSF
      BillionToOne at Stifel 2026 Healthcare Conference: growth broadens
      Nov 11Investing.comSF
      ProMIS Neurosciences at stifel 2026 healthcare conference: safety focus
      Nov 11Investing.comPMNSF
      Oculis at Stifel 2026 Healthcare Conference 2026: shift to neuroprotection
      Nov 11Investing.comOCSSF
      Immunic at Stifel 2026 Healthcare Conference 2026: MS data loom
      Nov 11Investing.comSF
      Kestra Medical at Stifel 2026 Healthcare Conference: growth, margins rise
      Nov 11Investing.comSF
      Atrium Therapeutics at stifel 2026 healthcare conference: cash, pipeline
      Nov 11Investing.comSF
      Mirum Pharmaceuticals at Stifel 2026 Healthcare Conference: growth broadens
      Nov 11Investing.comMIRMSF
      AtriCure at Stifel 2026 Healthcare Conference: growth stays broad
      Nov 11Investing.comSF
      Exelixis at Stifel 2026 Healthcare Conference: zanzalintinib push
      Nov 11Investing.comSF
      Stifel Just Cut Its CoreWeave Target From $120 to $60, Even After a Raised Outlook
      Nov 11Yahoo FinanceCRWVSF
      Olema Oncology at Stifel 2026 Healthcare Conference 2026: key trial inflection
      Nov 11Investing.comOLMASF
      Rhythm Pharmaceuticals at Stifel 2026 Healthcare Conference: launch gains pace
      Nov 11Investing.comSF

      This is the newest page. Registered accounts read further back.